Forbion

Tomorrow, March 8, marks International Women's Day, a global celebration of the social, economic, cultural, and political achievements of women. At Forbion, we are proud to recognize and celebrate the incredible women who contribute to our success, drive innovation, and inspire positive change across the life sciences industry. We remain committed to fostering an inclusive environment where all talent can thrive. Together, we celebrate the women who lead, innovate, and uplift those around them. Click on the video below to hear directly from some of the women at Forbion as they share their advice and insights. Machteld Groeneveld, LLM, MBA Silva Deželan, PhD Jennifer Fritzsche Rachelle Young Nanna Lüneborg #InternationalWomensDay #IWD2025 #InspireInclusion #Forbion #lifesciences #biotech #leaders

Forbion portfolio company Purespring Therapeutics, a pioneering company focused on transforming the treatment of kidney diseases, announces the appointment of Haseeb Ahmad as its Chief Executive Officer and member of the Board of Directors. He brings significant senior industry leadership, joining Purespring with over 25 years in the life sciences industry and an impressive track record of leading organisations to create blockbuster brands from primary care to rare diseases, across both mature and growth markets. Click on the following link to learn more: https://lnkd.in/e9VWsrce #lifesciences #portfoliocompany #news #appointment #venturecapital

Forbion portfolio company Orbis Medicines has named veteran R&D Leader Mikael Dolsten as its board chair. Dr. Dolsten was most recently CSO of Pfizer and has served in leadership roles at AstraZeneca, Boehringer Ingelheim, Pharmacia, and Wyeth Pharmaceuticals. His appointment follows the transition of Morten Graugaard from Chairperson to CEO earlier this year. Click on the following link to learn more: https://lnkd.in/edYPBTnc #appointment #lifesciences #biotech

Forbion is pleased to announce the appointment of Regina Salvat, PhD, as Principal in our Boston office. She holds a PhD in protein engineering from Dartmouth College and a degree in biomedical engineering from Cornell University. Regina is already a familiar face to Forbion, having collaborated with us on several successful investments. As part of the Forbion Growth team, she will focus on private and crossover opportunities, bringing her deep expertise and strong network to further strengthen our efforts. We are excited to continue expanding our team with exceptional talent and to further grow our presence in the US. Welcome, Regina! Read more using the following link: https://lnkd.in/earVQrsK #Forbion #LifeSciences #VentureCapital #GrowthInvesting #Biotech Regina Salvat

Today, on 28 February, we recognize Rare Disease Day and the millions of people around the world living with rare diseases. At Forbion, we are proud to have supported the development of innovative gene therapies and other transformative treatments for rare diseases. Our work spans early innovation, scientific insight, entrepreneurial support, and long-term partnership - all essential elements in bringing these therapies to life. Learn more about our role and our investment approach in advancing gene therapies and supporting innovation in the rare disease space: https://lnkd.in/en-zHitb #RareDiseaseDay #RareDiseases #GeneTherapy #Forbion #Biotech #Innovation

Forbion portfolio company LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington’s Disease, myotonic dystrophy type 1, and other triplet repeat expansion diseases, today announces the appointment of Dr Cyrus Mozayeni as its Chair of the Board of Directors. Dr Mozayeni is a highly experienced biotech entrepreneur with a track record of more than 20-years spearheading growth and strategic business development for life sciences companies. Read more about his appointment using the following link: https://lnkd.in/eUHX5JpC #biotech #lifesciences #Chair #moversandshakers #appointments Rogier Rooswinkel Gilles van Tienderen, PhD

The Sachs Associates 18th Annual European Life Sciences CEO Forum (#Sachs_ELSF) will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel. Forbion's Tim Lohoff, Ph.D., Senior Associate, will co-chair the New Modalities Panel: The Future of Gene Editing together with Victoria English, Co-Founder & Editor of MedNous (Evernow Publishing Ltd) Publishing Ltd. Panellists for this session on New Modalities will include: Albert Seymour, President & CEO, Forbion portfolio company Seamless Therapeutics, Inc. Avencia Sanchez-Mejias PhD, Co-Founder & CEO, Integra Therapeutics Monika Paule, Co-Founder, CEO & Board Member, Caszyme, LLC Paul Vogel, Managing Director & VP of Research, AIRNA Corporation, Inc. Sean Kendall, Partner, ARCH Venture Partners This panel will delve into the advancements in gene editing technologies such as CRISPR, TALENs, and ZFNs, examining their impact on medical research and treatment options. Learn from pioneers in the field about the latest developments, ethical considerations, and the road ahead for gene therapies. For more about this event click on the following link: https://lnkd.in/e-iHjzTw #event #lifesciences #leaders #biotech #venturecapital

We are pleased to share exciting news from our portfolio company, Navigator Medicines, Inc. The company has announced the appointments of Tausif ('Tosh') Butt as Chief Executive Officer and Khurem Farooq as Chairman of the Board of Directors. Tosh, formerly President of Idorsia Pharmaceuticals Ltd and Chief Operating Officer of ChemoCentryx, brings over 20 years of leadership experience across global pharmaceutical and biotech companies. Khurem, currently Chief Executive Officer of Verdiva Bio and previously CEO of Aiolos Bio and Gyroscope Therapeutics, brings more than 25 years of expertise in drug development and operational leadership. These strategic additions strengthen Navigator’s leadership as the company continues to advance NAV-240, a clinical-stage bispecific antibody targeting TNFα and OX40L, alongside its innovative pipeline of OX40L-based biologics for the treatment of complex autoimmune diseases. We look forward to seeing Navigator’s continued progress in addressing significant unmet medical needs in immunology. #Leadership #Biotech #Immunology #lifesciences Click on the following link to read more: https://lnkd.in/eVFpXUtn Wouter Joustra Audrey Cacaly Marc-Olivier Turgeon Mathias Vinther

On International Day of Women and Girls in Science, we proudly celebrate the remarkable contributions of women in STEM and honor the women of Forbion who are leading the way in biotech innovation and investment. Our team embodies the spirit of this day - driving impactful ventures, uncovering cutting-edge science, and shaping the future of healthcare.     Meet some of the exceptional women in our investment team:   - Nanna Lüneborg, PhD, MBA – General Partner - Audrey Cacaly, MSc - Principal  - Vanessa Carle, PhD – Senior Associate - Melanie de Almeida, PhD - Associate - Alice Vickers. PhD - Associate - Charlotte Koldeweij, MD, PhD – Fellow    Your dedication, expertise, and leadership inspire not just us but countless others across the industry. To all the women and girls in science around the globe: your work changes lives, advances knowledge, and makes the impossible possible. Today and every day, we celebrate you. Let us continue working together to empower women and girls in science. To learn more about our team members click on the following link: https://lnkd.in/gbPSvMx3    #InternationalDayOfWomenAndGirlsInScience #STEM #Innovation #DiversityInScience #Forbion #lifesciences #biotech   

We are pleased to welcome our new Fellows to the Forbion team. At Forbion, we strive to create meaningful impact through innovation and collaboration. Our new Fellows bring diverse expertise, fresh perspectives, and a shared commitment to shaping the future of healthcare and planetary health. Charlotte Koldeweij, MD, PhD has extensive experience in clinical research and has contributed to several publications in peer-reviewed journals. Charlotte is a medically trained doctor with clinical experience in pediatrics. She has worked in strategic consulting, policy-making and international development across the private and non-profit sectors in France, the Netherlands, Burkina Faso and the United Kingdom. Luuk de Vries is in the process of completing his PhD in neuroscience at the Netherlands Institute for Neuroscience. His research focused on resilience to Alzheimer’s disease, a phenomenon where individuals have significant amounts of Alzheimer’s disease neuropathology but no clinical symptoms, by generating multi-omic data from human brain tissue. His work has resulted in multiple high-impact papers, and he was awarded the Dick Swaab award. Roberto Hofmann holds a PhD in Synthetic Biology from the University of Cambridge and a BSc in Molecular Biology and Physics from University College London. During his studies, Roberto also worked at both McKinsey & Company and Equitas Capital. Roberto also spent two years as "Entrepreneur in Residence and Venture Coordinator" at The Sainsbury Laboratory, an entity focused on creating ventures in targeted protein degradation and genetic crop protection. Joseph Iwasyk has experience at several tech startups and research institutions namely, Tecan in the Advanced Technology Group, Research at the Center for Neurodegenerative Disease Research at Perelman Med and at the Swiss Tropical and Public Health Institute. Joseph graduated from ETH Zurich with a MSc in Molecular Biomedical Engineering and holds a BSc in Bioengineering from the University of Pennsylvania. Learn more about each team member by clicking on the following link: https://lnkd.in/gbPSvMx3 We look forward to making a difference together! #welcome #forbion #venturecapital #lifesciences #planetaryhealth #teamwork #team